PMID- 29270762
OWN - NLM
STAT- MEDLINE
DCOM- 20180726
LR  - 20181113
IS  - 1993-1352 (Electronic)
IS  - 1672-0733 (Linking)
VI  - 37
IP  - 6
DP  - 2017 Dec
TI  - Hepatic resection combined with radiofrequency ablation versus hepatic resection 
      alone for multifocal hepatocellular carcinomas: A meta-analysis.
PG  - 974-980
LID - 10.1007/s11596-017-1836-3 [doi]
AB  - This meta-analysis aimed to comprehensively assess the efficacy and safety of 
      hepatic resection combined with radiofrequency ablation versus hepatic resection 
      (HR) alone for the treatment of multifocal hepatocellular carcinomas (HCC). A 
      literature search was conducted from the database including MEDLINE, Embase, 
      Cochrane Central Register of Controlled Trials (CENTRAL) and China Biology 
      Medicine (CBM) disc. The primary outcomes included the 1-, 3-, 5-year overall 
      survival (OS) and disease-free survival (DFS) rate. The secondary outcomes 
      contained the intraoperative parameters and postoperative adverse events (AEs). 
      These parameters were all analyzed by RevMan 5.3 software. After carefully 
      screening relevant studies, four retrospective studies of high quality involving 
      466 patients (197 in the combined group and 269 in the HR group) were included in 
      this study. The pooled results showed that the 1-, 3-, 5-year OS rate in the 
      combined group were comparable with those in the HR group (OR=0.77, 0.96, 0.88; 
      P=0.33, 0.88, 0.70, respectively). Similarly, there was no significant difference 
      in 1-, 3-, 5-year DFS rate between the combined group and the HR alone group 
      (OR=0.57, 0.83, 0.72; P=0.17, 0.37, 0.32, respectively). And the intraoperative 
      parameters and postoperative AEs were also comparable between the above two 
      cohorts. However, two included studies reported that tumor often recurred in the 
      ablation site in the combined group. The present meta-analysis indicated that the 
      HR combined with RFA could reach a long-term survival outcome similar to curative 
      HR for multifocal HCC patients. And this therapy may be a promising alternative 
      for these patients with marginal liver function or complicated tumor 
      distribution. Furthermore, high quality randomized controlled trials (RCTs) are 
      imperative to verify this conclusion.
FAU - Xu, Liang-Liang
AU  - Xu LL
AD  - Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, 
      610041, China.
FAU - Zhang, Ming
AU  - Zhang M
AD  - Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, 
      610041, China.
FAU - Yi, Peng-Sheng
AU  - Yi PS
AD  - Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, 
      610041, China.
FAU - Zheng, Xiao-Bo
AU  - Zheng XB
AD  - Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, 
      610041, China.
FAU - Feng, Lei
AU  - Feng L
AD  - Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, 
      610041, China.
FAU - Lan, Chuan
AU  - Lan C
AD  - Institute of Hepatobiliary, Pancreatic and Intestinal Diseases, North Sichuan 
      Medical College, Nanchong, 637000, China.
AD  - Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical 
      College, Nanchong, 637000, China.
FAU - Tang, Jian-Wei
AU  - Tang JW
AD  - Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, 
      610041, China.
FAU - Ren, Sheng-Sheng
AU  - Ren SS
AD  - Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, 
      610041, China.
FAU - Xu, Ming-Qing
AU  - Xu MQ
AD  - Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, 
      610041, China. xumingqing0018@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20171221
PL  - China
TA  - J Huazhong Univ Sci Technolog Med Sci
JT  - Journal of Huazhong University of Science and Technology. Medical sciences = Hua 
      zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. 
      Yixue Yingdewen ban
JID - 101169627
SB  - IM
MH  - Aged
MH  - Carcinoma, Hepatocellular/mortality/pathology/*surgery
MH  - Catheter Ablation/*methods
MH  - Female
MH  - Hepatectomy/*methods
MH  - Humans
MH  - Liver Neoplasms/mortality/pathology/*surgery
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/mortality/pathology/*surgery
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - hepatic resection
OT  - long-term survival outcome
OT  - multifocal hepatocellular carcinoma
OT  - radiofrequency ablation
EDAT- 2017/12/23 06:00
MHDA- 2018/07/27 06:00
CRDT- 2017/12/23 06:00
PHST- 2016/12/30 00:00 [received]
PHST- 2017/08/31 00:00 [revised]
PHST- 2017/12/23 06:00 [entrez]
PHST- 2017/12/23 06:00 [pubmed]
PHST- 2018/07/27 06:00 [medline]
AID - 10.1007/s11596-017-1836-3 [pii]
AID - 10.1007/s11596-017-1836-3 [doi]
PST - ppublish
SO  - J Huazhong Univ Sci Technolog Med Sci. 2017 Dec;37(6):974-980. doi: 
      10.1007/s11596-017-1836-3. Epub 2017 Dec 21.